Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)

Piccart, M.Ruiz Borrego, M.Duhoux, F.Arkenau, H-T.Doger de Speville, B.Wildiers, H.Campone, M.Tosi, D.Garcia-Corbacho, J.Jimenez, B.Escriva-de Romani, S.Wardley, A. M.Tassone, P.Boni, V.Jerez, Y.Aftimos, P. G.Hennequin, A.Amair-Pinedo, F.Pellacani, A. U. E.Laurent, D. O.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/27097enResults of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC)conference outputopen access10.1016/j.annonc.2020.08.4491569-8041http://www.annalsofoncology.org/article/S0923753420404454/pdf573469100347